Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

Blood

Volumn 115, Issue 3, 2010, Pages 636-642

  Bullinger, Lars ^a   Ehrich, Mathias ^b   Döhner, Konstanze ^a   Schlenk, Richard F ^a   Döhner, Hartmut ^a   Nelson, Matthew R ^c   Van Den Boom, Dirk ^b  

^a UNIVERSITY OF ULM   (Germany)

^b SEQUENOM INC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL; CHROMOSOME 17; CHROMOSOME ANALYSIS; DNA MICROARRAY; DNA SEQUENCE; GENETICS; METHODOLOGY; MORTALITY; MULTIVARIATE ANALYSIS; PHYSIOLOGY; VALIDATION STUDY;

ADULT; CHROMOSOMES, HUMAN, PAIR 17; CPG ISLANDS; CYTOGENETIC ANALYSIS; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 77449157068     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-211003     Document Type: Article

References (40)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894- 1907.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
4. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
5. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
6. Döohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica. 2008;93(7):976-982.
7. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350(16):1605-1616. (Pubitemid 38501163)
8. Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood. 2005;106(4):1189-1198. (Pubitemid 41130867)
9. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628. (Pubitemid 38528701)
10. Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108(2):685-696.
11. Bullinger L, Dohner K, Kranz R, et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood. 2008;111(9):4490-4495.
12. Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38(5):285-303.
13. Feinberg AP. Methylation meets genomics. Nat Genet. 2001;27(1):9-10.
14. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253-266.
15. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428.
16. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97(9):2823-2829.
17. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988-993.
18. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene SLC5A8 in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008:112(5):2013-2016.
19. Wouters BJ, Jorda MA, Keeshan K, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007;110(10):3706-3714. (Pubitemid 350159640)
20. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112(4):1366- 1373.
21. Hackanson B, Bennett KL, Brena RM, et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res. 2008;68(9):3142-3151.
22. Agrawal S, Unterberg M, Koschmieder S, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007;67(3):1370-1377. (Pubitemid 46270798)
23. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785-15790. (Pubitemid 41552820)
24. Agrawal S, Hofmann WK, Tidow N, et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007;109(9):3895-3905. (Pubitemid 46641742)
25. Raval A, Tanner SM, Byrd JC, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007;129(5):879-890. (Pubitemid 46813150)
26. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750. (Pubitemid 41102131)
27. Schlenk RF, Frohling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18(11):1798-1803. (Pubitemid 39534320)
28. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280-3288.
29. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www.ncbi.nlm.nih.gov/geo. Accessed December 6, 2009.
30. The R Development Core Team. R: A Language and Environment for Statistical Computing. 2003. http://cran.r-project.org/doc/manuals/refman.pdf. Accessed December 6, 2009.
31. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004;2(4):E108. (Pubitemid 39234509)
32. Bair E, Tibshirani R. Superpc for R: Tutorial. http://www-stat.stanford. edu/~tibs/superpc/tutorial.html. Accessed December 6, 2009.
33. Ripley BD. Pattern Recognition and Neural Networks. Cambridge, United Kingdom: Cambridge University Press; 1996.
34. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006;38(5):540-549.
35. Grubach L, Juhl-Christensen C, Rethmeier A, et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol. 2008;81(2):112-122.
36. Cokus SJ, Feng S, Zhang X, et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008;452(7184):215-219.
37. Gebhard C, Schwarzfischer L, Pham TH, et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res. 2006;66(12):6118-6128.
38. Schilling E, Rehli M. Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics. 2007;90(3):314-323. (Pubitemid 47176332)
39. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971-3993. (Pubitemid 46218700)
40. Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol. 2005;23(17):3957-3970. (Pubitemid 46218699)